Baidu
map

JAMA子刊:早发房颤、心肌病及心律失常的罕见基因突变的流行率

2021-09-23 MedSci原创 MedSci原创

心房颤动(AF)是最常见的心律失常疾病,影响着全球3000多万人。

心房颤动(AF)是最常见的心律失常疾病,影响着全球3000多万人。心房颤动是心力衰竭或中风的重要原因,导致心房颤动患者的死亡风险增加。由于全球老龄化趋势,预测房颤的发病率将进一步增加,相关的社会经济负担也在不断增加。

其中,早发心房颤动(AF)可能是更严重的潜在遗传性心肌病或心律失常综合征的最初表现。为了研究早发房颤的基因检测结果,来自美国范德比尔特大学医学中心血管部的专家开展了一项研究,结果发表在JAMA Cardiology杂志上。

这项前瞻性、观察性队列研究招募了来自一个学术性医疗中心的参与者,他们在66岁之前被诊断为房颤,并通过国家心肺和血液研究所的精准医疗计划的跨基因组测序。参与者从1999年11月23日到2015年6月2日入选。暴露因素为在商业性临床基因检测实验室使用的心肌病和心律失常面板上的145个基因中发现了罕见的变异。

主要结果和措施是测序数据采用自动程序进行分析,然后由独立的盲审员小组进行人工审查。主要结果是使用美国医学遗传学和基因组学学院的标准对罕见变异进行分类:良性、可能是良性、意义未定的变异、可能致病或致病。与疾病相关的变异被定义为与常染色体显性或X连锁显性疾病相关的基因中的致病/可能致病的变异。

结果在1293名参与者中(934名[72.2%]男性;入组时年龄中位数[四分位数范围]为56[48-61]岁;房颤诊断时年龄中位数[IQR]为50[41-56]岁),基因检测发现131人(10. 1%)有疾病相关的变异,812人(62.8%)有意义不明的变异,92人(7.1%)是常染色体隐性疾病的杂合子携带者,258人(20.0%)没有可疑变异。

疾病相关突变的流行以及与遗传性心肌病和心律失常综合征的遗传重叠情况

总的来说,在30岁以前诊断为房颤的参与者中,出现疾病相关变异的可能性最高(16.8%;95%CI,10.0%-23.6%]),60岁以后最低(7.1%;95%CI,2.4%-11.9%])。与遗传性心肌病综合征相比,与房颤相关的变异与遗传性心律失常的关系更高。最常见的基因是TTN(n = 38),MYH7(n = 18),MYH6(n = 10),LMNA(n = 9),和KCNQ1(n = 8)。

综上,在这项队列研究中,基因检测在10%的早发房颤患者中发现了与疾病相关的变异。如果在30岁以前诊断,该比例更高,如果在60岁以后诊断,该比例更低。大多数致病/可能致病的变异都在与心肌病有关的基因中。这些结果支持在早发的房颤中使用基因检测。

 

参考文献:

Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes. JAMA Cardiol. Published online September 08, 2021. doi:10.1001/jamacardio.2021.3370

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720744, encodeId=2c5f1e20744bf, content=<a href='/topic/show?id=a7ff65385f1' target=_blank style='color:#2F92EE;'>#流行率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65385, encryptionId=a7ff65385f1, topicName=流行率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44c32960238, createdName=lixiaol, createdTime=Sat Jan 29 16:46:16 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664126, encodeId=a1121664126b5, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Thu Nov 25 14:46:16 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945986, encodeId=c7d21945986ba, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 17 12:46:16 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467630, encodeId=b290146e630f2, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Sep 25 00:46:16 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622500, encodeId=49141622500d0, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Sep 25 00:46:16 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2022-01-29 lixiaol
  2. [GetPortalCommentsPageByObjectIdResponse(id=1720744, encodeId=2c5f1e20744bf, content=<a href='/topic/show?id=a7ff65385f1' target=_blank style='color:#2F92EE;'>#流行率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65385, encryptionId=a7ff65385f1, topicName=流行率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44c32960238, createdName=lixiaol, createdTime=Sat Jan 29 16:46:16 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664126, encodeId=a1121664126b5, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Thu Nov 25 14:46:16 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945986, encodeId=c7d21945986ba, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 17 12:46:16 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467630, encodeId=b290146e630f2, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Sep 25 00:46:16 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622500, encodeId=49141622500d0, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Sep 25 00:46:16 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1720744, encodeId=2c5f1e20744bf, content=<a href='/topic/show?id=a7ff65385f1' target=_blank style='color:#2F92EE;'>#流行率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65385, encryptionId=a7ff65385f1, topicName=流行率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44c32960238, createdName=lixiaol, createdTime=Sat Jan 29 16:46:16 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664126, encodeId=a1121664126b5, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Thu Nov 25 14:46:16 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945986, encodeId=c7d21945986ba, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 17 12:46:16 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467630, encodeId=b290146e630f2, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Sep 25 00:46:16 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622500, encodeId=49141622500d0, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Sep 25 00:46:16 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1720744, encodeId=2c5f1e20744bf, content=<a href='/topic/show?id=a7ff65385f1' target=_blank style='color:#2F92EE;'>#流行率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65385, encryptionId=a7ff65385f1, topicName=流行率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44c32960238, createdName=lixiaol, createdTime=Sat Jan 29 16:46:16 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664126, encodeId=a1121664126b5, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Thu Nov 25 14:46:16 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945986, encodeId=c7d21945986ba, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 17 12:46:16 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467630, encodeId=b290146e630f2, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Sep 25 00:46:16 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622500, encodeId=49141622500d0, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Sep 25 00:46:16 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2021-09-25 syscxl
  5. [GetPortalCommentsPageByObjectIdResponse(id=1720744, encodeId=2c5f1e20744bf, content=<a href='/topic/show?id=a7ff65385f1' target=_blank style='color:#2F92EE;'>#流行率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65385, encryptionId=a7ff65385f1, topicName=流行率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44c32960238, createdName=lixiaol, createdTime=Sat Jan 29 16:46:16 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664126, encodeId=a1121664126b5, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Thu Nov 25 14:46:16 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945986, encodeId=c7d21945986ba, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 17 12:46:16 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467630, encodeId=b290146e630f2, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Sep 25 00:46:16 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622500, encodeId=49141622500d0, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Sep 25 00:46:16 CST 2021, time=2021-09-25, status=1, ipAttribution=)]

相关资讯

Neurology:房颤、卒中和无症状脑血管疾病的关系

AF与广泛的脑血管病变有关。需要进一步研究以确定是否可以将脑血管MRI标志物添加到当前的治疗指南中,以进一步个性化AF患者的抗凝治疗,并进一步归纳AF与脑血管疾病以及痴呆之间关联的潜在发病机制。

Stroke:华法林和4种直接口服抗凝剂对房颤患者痴呆风险的影响有何不同?

在这个庞大的亚洲房颤人群中,总体上,DOAC具有与华法林相似的痴呆风险。在65至74岁或有卒中病史的人群中,DOAC似乎比华法林更有益。对于特定的DOAC,与华法林相比,只有依度沙班与更低的痴呆风险相

Circulation:早期心律控制治疗给心衰合并房颤的患者带来的临床益处

有心衰体征或症状的患者确诊合并房颤后 1 年内开始心律控制治疗可带来显著的临床益处

J INTERN MED:较高针对apoB100 p210的自身抗体水平与女性较低的房颤发生率相关

心房颤动(AF)与全身和心房组织炎症相关。这些结果支持自身体液免疫与房颤之间的关联。

ESC 2021丨马长生教授:预期ETNA-AF中国研究结果将与国际一致,艾多沙班在大多数房颤患者中具有优势

ESC 2021大会上多项ETNA-AF研究结果发布,一起来看下我国房颤抗凝的现状吧。

Lancet Neurol:当房颤遇上自发性颅内出血,患者还能不能口服抗凝治疗?

当房颤遇上自发性颅内出血,患者还能不能口服抗凝治疗?

拓展阅读

用 TAVR 治疗 AFib 患者仍与风险升高有关

发表于《加拿大心脏病学杂志》研究显示,现代 TAVR 设备虽降低不良后果发生率,但基线房颤患者接受 TAVR 仍存风险,永久性房颤患者结果更差,多种因素与不良预后相关。

JAMA:桑才华/蒋晨阳/董建增/马长生团队研究发现房颤导管消融改良2C3L术式明显优于PVI(PROMPT-AF研究)

PROMPT-AF研究结果使令人振奋的,对于推动房颤消融领域的发展具有重要意义。在PROMPT-AF研究发表前,没有一项随机对照临床研究能证明PVI联合线性消融可提高房颤手术成功率。

GW-ICC 2024报道 | 《心房颤动射频导管消融技术规范》系列团体标准发布会

各位嘉宾就《心房颤动射频导管消融技术规范》系列团体标准的多个核心议题畅所欲言。

向全球推介乡村医生主导的房颤管理新模式!陈明龙教授解读MIRACLE-AF研究 | ESC 2024

中国医学论坛报社特别邀请陈明龙教授对MIRACLE-AF研究进行深入解读,介绍心房颤动管理新模式在我国乡村医疗中的应用价值和推广意义。

Eur J Heart Fail:心房颤动消融对终末期心力衰竭心律失常负荷和心室功能的影响:CASTLE-HTx 的经验教训

本研究结果为晚期心力衰竭合并房颤患者提供了新的治疗方案,提示房颤消融作为辅助治疗,能够减轻患者的病理性房颤负担,改善心功能,有助于减少心力衰竭的并发症,延缓患者进入终末期阶段的进展。

房颤消融术中ST段抬高,如何处理?贵州学者经验

研究者指出,术前除冠脉造影明确冠脉狭窄程度外,评估冠脉微循环障碍可能具有一定的临床价值。

Baidu
map
Baidu
map
Baidu
map